US FDA Warns Docs On Gastric Balloon Adverse Events
Executive Summary
Gastric balloons from ReShape Medical and Apollo Endosurgery have been tied to pancreatitis and problems caused by over-inflation, the agency says.
You may also be interested in...
Market Intel: Intragastric Balloons And Other Innovations To Inflate Weight Loss Devices Market
The global market for minimally invasive weight loss devices is expected to grow to $290m by 2021, a CAGR of 16%, driven in large part by the rising obesity epidemic and associated Type 2 diabetes. Meddevicetracker expects that enhancements and innovations, particularly in the growing intragastric balloon market, and emerging technologies by smaller companies, will lead the growth in the overall weight loss devices market. In this feature, we'll take a closer look at the overall market and regional landscape and take a deep dive into the fastest-growing intragastric balloon segment, providing key insights from a bariatric surgeon on the pros and cons of these technologies.
Gastric Balloon-Makers Respond To US FDA Warning
Apollo Endosurgery and Reshape Medical are both defending their products’ safety in the wake of a US FDA letter warning of five deaths tied to the companies' intragastric balloon devices.
US FDA Warns of Deaths Tied To Gastric Balloons
The agency doesn’t yet know the exact causes of the five deaths. This is the second safety alert on the obesity-treatment devices this year.